We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Talazoparib Dual-targeting on Poly (ADP-ribose) Polymerase-1 and -16 Enzymes Offers a Promising Therapeutic Strategy in Small Cell Lung Cancer Therapy: Insight from Biophysical Computations.
- Authors
Mgoboza, Chwayita; Okunlola, Felix O.; Akawa, Oluwole B.; Aljoundi, Aimen; Soliman, Mahmoud E. S.
- Abstract
In recent times, inhibition of poly (ADP-ribose) polymerase (PARP) enzymes by pharmacological drugs has attracted much attention as an anticancer therapy. As reported, PARP-16 has been discovered as a novel anticancer target for small cell lung cancer, and that the inhibition of both PARP-16 and PARP-1 by talazoparib can increase the overall effectiveness of talazoparib in the SCLC treatment. In this study, we employed computational approaches to investigate the differential inhibitory potency of Talazoparib on PARP-1 and PARP-16. Talazoparib has excellent PARP-1 and PARP-16 binding activities, as revealed by the ΔGbind (total binding energy). Pp16-tpb had binding energy of −34.85 kcal/mol, while pp1-tpb had a binding energy of −26.36 kcal/mol. The binding activity of Talazoparib on both PARP-1 and PARP-16 was significantly influenced by van der Waal and electrostatic interactions. Correspondingly, according to the findings of this study, binding residues with total binding energy greater than 1.00 kcal/mol contributed considerably to the Talazoparib's binding activities on PARP-1 and PARP-16. We believe the findings of this study will pave the way for developing dual targeting of PARP enzymes as a strategy for small-cell lung cancer treatment.
- Subjects
SMALL cell lung cancer; ADP-ribosylation; ADENOSINE diphosphate; BINDING energy; ENZYMES; CANCER treatment; POLY(ADP-ribose) polymerase
- Publication
Cell Biochemistry & Biophysics, 2022, Vol 80, Issue 3, p495
- ISSN
1085-9195
- Publication type
Article
- DOI
10.1007/s12013-022-01075-3